Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2018-06-19 Declaration of Voting R…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Notification of Major Holdings' and details changes in voting rights percentages held by BlackRock, Inc. in MorphoSys AG, referencing specific sections of the German Securities Trading Act (WpHG). This type of filing, which reports changes in significant share ownership thresholds, directly corresponds to the definition of a Major Shareholding Notification. The date of the event (12 Jun 2018) and the notification date (19 June 2018) confirm it is a timely regulatory disclosure regarding ownership structure, matching the criteria for code MRQ.
2018-06-19 English
MorphoSys Presents Clinical Data with Blood Cancer Candidate MOR208 in Chronic Lymphocytic Leukemia at EHA 2018 Conference (news with additional features)
Regulatory Filings Classification · 99% confidence The document is a news release dated June 15, 2018, announcing the presentation of clinical data for the drug candidate MOR208 at the EHA 2018 Conference. It details preliminary safety and efficacy results from the COSMOS trial. This type of announcement, which disseminates key scientific or operational updates outside of mandatory periodic financial reports (like 10-K or IR), is typically classified as a general Regulatory Filing or News Release. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change, the most appropriate general category for significant, non-financial corporate news disseminated via services like DGAP (which is mentioned) is Regulatory Filings (RNS), as it serves as a broad regulatory disclosure mechanism for material information not covered by other specific codes. The document length is substantial (12,456 chars), indicating it is the content itself, not just a brief announcement of a report.
2018-06-15 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains sections like 'Notification of Major Holdings', detailing changes in voting rights percentages (crossing thresholds like 3%) by a shareholder (BlackRock, Inc.) as of a specific date (07 Jun 2018). This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels. The filing code for this is MRQ.
2018-06-13 English
New Phase 3 Clinical Trials by MorphoSys's Partner with Gantenerumab in Early Alzheimer's Disease now Underway (news with additional features)
Regulatory Filings Classification · 99% confidence The document is a news release dated June 12, 2018, originating from MorphoSys AG, disseminated via DGAP (a service often used for regulatory news). The content announces the commencement of new Phase 3 clinical trials for Gantenerumab in Alzheimer's disease. It details the study design (GRADUATE-1 and GRADUATE-2), endpoints, and partnership with Roche. This type of announcement, focusing on clinical trial progress and partnership updates, is typically classified as a general corporate news release or an announcement related to R&D/pipeline progress. Since there is no specific category for 'Clinical Trial Updates' or 'R&D News', and it is a formal announcement of a significant corporate event (not a financial report like 10-K, ER, or IR), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous corporate news that doesn't fit other specific financial reporting codes. It is not an Earnings Release (ER), Interim Report (IR), or a formal SEC filing like 10-K or DEF 14A.
2018-06-12 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains sections like 'Notification of Major Holdings', detailing changes in voting rights percentages (crossing thresholds) held by BlackRock, Inc. in MorphoSys AG, referencing German Securities Trading Act (WpHG) sections. This directly corresponds to the definition of a notification regarding changes in significant share ownership levels, which aligns best with the 'Major Shareholding Notification' category (MRQ). Although it mentions 'Voting Rights Announcements' in the header, MRQ is the specific category for reporting changes in holdings that cross thresholds, which is the core content here.
2018-06-11 English
Declaration of Voting Results & Voting Rights Announcements 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Notification of Major Holdings' and details changes in voting rights percentages held by BlackRock, Inc. in MorphoSys AG, referencing specific German securities trading act sections (WpHG). This type of filing, which reports changes in significant share ownership thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is a formal regulatory disclosure, not a general announcement of a report (RPA) or a broad regulatory filing (RNS).
2018-06-08 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.